Erwinase for intramuscular injection 10000 use-results survey
- Conditions
- acute leukemia or malignant lymphoma (only in cases of hypersensitivity to L-asparaginase products)Erwinase, acute leukemia, malignant lymphoma
- Registration Number
- JPRN-jRCT2031230366
- Lead Sponsor
- Osawa Mistuharu
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 180
Patients who fall under either of the following 1) or 2) and have been treated with this drug are eligible.
1) Patients with acute leukemia (including cases of acute conversion of chronic leukemia) or malignant lymphoma
However, only in cases of hypersensitivity to L-asparaginase products.
(2) Patients enrolled in a multicenter late phase II clinical trial for T-cell acute lymphoblastic leukemia in children, AYA generation and adults (JPLSG-ALL-T19) and a multicenter phase III clinical trial of multi-agent chemotherapy for B-precursor cell acute lymphocytic leukemia in children, AYA and adults (JPLSG-ALL -B19) enrolled patients.
1) Patients with a history of serious hypersensitivity to any ingredient of Irwinase for Intramuscular Injection 10000
(2) Patients with a history of serious pancreatitis caused by L-asparaginase products
3) Pregnant women or women who may be pregnant
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method